NCT02870231

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

A Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 187 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity

Conditions

• Metabolism and Nutrition Disorder
• Obesity

Interventions

Type	Name	Description
DRUG	NNC9204-0530	Once-daily subcutaneous (s.c., under the skin) administration.
DRUG	liraglutide	Once-daily subcutaneous (s.c., under the skin) administration.
DRUG	placebo	Once-daily subcutaneous (s.c., under the skin) administration

Timeline

• Start date: 2016-08-18
• Primary completion: 2017-09-03
• Completion: 2017-09-03
• First posted: 2016-08-17
• Last updated: 2018-09-05

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study